Morgan Stanley Oyster Point Pharma, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$7.95 - $11.68 $1.09 Million - $1.59 Million	-136,542 Reduced 94.47%	7,986 $89,000
Q3 2022 Nov 14, 2022	BUY	$4.41 - $8.38 $2,103 - $3,997	477 Added 0.33%	144,528 $812,000
Q2 2022 Oct 27, 2022	BUY	$3.6 - $11.2 $141,487 - $440,182	39,302 Added 37.52%	144,051 $623,000
Q2 2022 Aug 15, 2022	BUY	$3.6 - $11.2 $141,487 - $440,182	39,302 Added 37.52%	144,051 $623,000
Q1 2022 Oct 27, 2022	SELL	$8.58 - $17.65 $337,211 - $693,680	-39,302 Reduced 27.28%	104,749 $1.22 Million
Q1 2022 May 13, 2022	BUY	$8.58 - $17.65 $276,327 - $568,435	32,206 Added 44.4%	104,749 $1.22 Million
Q4 2021 Feb 14, 2022	SELL	$10.17 - $18.96 $459,531 - $856,707	-45,185 Reduced 38.38%	72,543 $1.33 Million
Q3 2021 Nov 15, 2021	BUY	$11.67 - $18.07 $1.37 Million - $2.13 Million	117,728 New	117,728 $1.4 Million

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.